Navigation Links
Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
Date:7/12/2011

SAN DIEGO, July 12, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today results from a Phase 1 clinical trial of APD811, an orally bioavailable agonist of the prostacyclin receptor which is intended for the treatment of pulmonary arterial hypertension, or PAH.

The randomized, double-blind and placebo-controlled trial evaluated the safety, tolerability and pharmacokinetics of 0.03 mg, 0.05 mg, 0.1 mg and 0.2 mg single doses of APD811. The trial evaluated 32 healthy volunteers in four cohorts of eight participants each – six randomized to APD811 and two to placebo. APD811 was rapidly absorbed and demonstrated dose-proportional pharmacokinetic exposure over the tested dose range. The terminal half-life was approximately 20 hours.

The most frequent treatment-emergent adverse events were headache, vomiting, nausea, jaw pain and flushing. Dose-limiting adverse events of nausea and vomiting occurred at the 0.2 mg dose. As compared to placebo, heart rate trended higher at the 0.05 mg, 0.1 mg and 0.2 mg doses and the corrected QT (QTc) interval trended higher at the 0.1 mg and 0.2 mg doses. Arena believes the QTc observation is not supported by preclinical data and will further evaluate this in future studies. No serious adverse events were reported.

"We are encouraged by the results of this early stage clinical trial that suggest APD811 has the potential for once-daily, oral dosing, and our next step will be to evaluate the safety, tolerability and pharmacokinetics of multiple dosing and the optimal titration schedule in a Phase 1b trial," said William R. Shanahan, M.D., Arena's Senior Vice President and Chief Medical Officer. "The development of APD811 is the result of Arena's continuing commitment to advance our diverse research and development pipeline."

About Pulmonary Arterial Hypertension (PAH)PAH is a progressi
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
2. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
3. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
4. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
5. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
6. Arena Pharmaceuticals Expands GPR119 Patent Portfolio for Type 2 Diabetes
7. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11
8. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
9. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
10. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
11. Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014  Heated dialogue in recent months about the ... treatments to Gilead,s new hepatitis C drug Harvoni® – ... questioning what it means to put a price on ... And while drug pricing is one of the most ... a general business and ethical standpoint – it is ...
(Date:11/21/2014)... 2014 Clementia Pharmaceuticals, Inc. ... (EMA) has granted Orphan Medicinal Product Designation ... for the treatment of fibrodysplasia ossificans progressiva ... genetic disease characterized by painful, recurrent episodes ... abnormal bone formation. This process, known as ...
(Date:11/21/2014)... Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ... Executive Officer, will be presenting at the 26 th ... Hotel in New York . The formal ... PM ET. In addition, Mr. Krakauer and Jorgen B. ... one-on-one meetings during the day. An audio ...
Breaking Medicine Technology:"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 3"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 4"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 5Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3
... AstraZeneca (NYSE: AZN ) announced today that Judge Joseph ... that the substance patent protecting CRESTOR (RE37,314 – the ,314 patent) is valid ... committed by any Shionogi employee. The court also held the ,314 patent to ... , , ...
... June 29 Dr. Harry J. Guttman, Esq. , Of ... participant at the 2010 Central Regional Meeting of the American Chemical Society ...  The 2010 CeRMACS attracted over 400 participants and focused on small business ... , , ...
Cached Medicine Technology:CRESTOR® Patent Upheld By US Court 2CRESTOR® Patent Upheld By US Court 3Dr. Harry J. Guttman, Esq. Invited Speaker at 2010 Central Regional Meeting of the American Chemical Society 2
(Date:11/22/2014)... Recently, UWDress.com, a successful wedding dress shop, has released its ... order to prepare for the wedding season. All of them ... , UWDress.com is a reliable company that has many years ... items -- formal wedding guest attire. This new collection comes ... and princess. As one of the leading companies in the ...
(Date:11/22/2014)... New York, NY (PRWEB) November 22, 2014 ... Australia’s Therapeutics Goods Administration (TGA) approved it for ... Glutathione was approved and listed within the Therapeutic ... http://www.comlaw.gov.au/Details/F2014L01277 , Kyowa Hakko’s Setria® Glutathione ... Chem, a biotech specialist that sources and imports ...
(Date:11/22/2014)... PA (PRWEB) November 22, 2014 "My ... the pain caused by the machine," said an inventor ... she had to go back a second time because ... invention idea." , She developed the patent-pending MAMO EASY ... breast cancer. The design saves the patient from the ...
(Date:11/22/2014)... November 22, 2014 Lipitor lawsuits ( ... patients who allegedly developed Type 2 diabetes due to ... multidistrict litigation now underway in U.S. District Court, District ... court documents, the litigation will convene its next Status ... has directed Lead Counsel for Plaintiffs and Defendants to ...
(Date:11/22/2014)... 2014 The Sports Conflict Institute ... to its team of conflict resolution professionals. Baroff comes ... and referee. He has over 30 years experience as an ... “I'm very excited to connect with SCI and bring my ... to a program with a complete sports focus,” says Baroff. ...
Breaking Medicine News(10 mins):Health News:Formal Wedding Guest Attire Added to UWDress.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:SCI Announces New Team Member Roy Baroff 2Health News:SCI Announces New Team Member Roy Baroff 3
... Health Management Systems,Inc. (HMS) announced today that it ... in Medford, Massachusetts, to provide coordination of,benefits services. ... than 150,000 MassHealth and Commonwealth Care members across,Massachusetts., ... will identify third party coverage for claims already ...
... CHARLOTTE, N.C., Dec. 12 CG Technology has ... better reflecting the depth,and breadth of services it ... high quality and standards of work, while focusing ... Carlisle & Gallagher Consulting Group (CG) is a ...
... 12 ATS Medical, Inc.,(Nasdaq: ATSI ), ... services, today announced that James L. Cox, M.D. ... Dr. Cox, reputation as a,preeminent authority in the ... that serves as the foundation for ATS 3f(R),tissue ...
... to six community organizations in ... underserved areas, WOODLAND HILLS, ... a total of $30,000 in end of,year donations to various food banks ... agencies in northern and,southern California to assist vulnerable populations., Blue Cross ...
... An improved understanding of the effects of regulation ... designed to advance entrepreneurship, according to a new ... for Entrepreneurship Public Policy report provides an overview ... system can discourage or encourage the entrepreneurial spirit. ...
... Dec. 11 Biodel Inc. (Nasdaq:,BIOD) today reported ... financial results, updated pipeline progress and disclosed 2008,objectives., ... public company, we advanced our pipeline,and achieved critical ... of Biodel. "The significant milestones reached include our,successful ...
Cached Medicine News:Health News:Network Health Awards Contract to HMS for Coordination of Benefits 2Health News:ATS Medical Appoints James L. Cox, M.D. as Medical Director 2Health News:ATS Medical Appoints James L. Cox, M.D. as Medical Director 3Health News:Blue Cross of California Gives $30,000 in Holiday Donations to Food Banks Throughout the State 2Health News:Rand study examines the effect of policy on entrepreneurship and small businesses 2Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 2Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 3Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 4Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 5Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 6Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 7Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 8Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 9
... 420 CPAP System includes the 420E Auto-CPAP ... can enjoy the advantages of the worlds ... devices. The GoodKnight 420E model records up ... includes other features of the 420S model. ...
Paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Safety Blood Collection Sets are supplied in three packaging variations, either with or without Luer Adapter and respectively a version with Luer Adapter and Tube Holder....
Simplicity and multi-directional retraction for a broad range of abdominal procedures...
Medicine Products: